Jonathan DiVincenzo, an officer of Bio-Rad Laboratories, Inc., filed a Form 144 notice of proposed sale of securities with the SEC on November 9, 2026, disclosing plans to sell 919 shares of Bio-Rad common stock on NYSE.
Key Highlights
- Seller: Jonathan DiVincenzo, identified in the filing as an officer of Bio-Rad Laboratories, Inc.
- Shares proposed for sale: 919 shares of Bio-Rad common stock, with an aggregate market value of $358,841.93 according to the filing.
- Approximate sale date: November 9, 2026, to be executed on the NYSE.
- Acquisition details: The 919 shares were acquired on October 24, 2025, through a restricted stock transaction from the issuer, with payment noted as "Not Applicable."
- Shares outstanding: The filing reports 21,832,130 shares of Bio-Rad common stock outstanding.
- Prior sales: The filing reports nothing to report for securities sold during the past three months.
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the executing broker.
DiVincenzo's Proposed Rule 144 Sale of Restricted Bio-Rad Shares
According to the Form 144 filing, Jonathan DiVincenzo, an officer of Bio-Rad Laboratories, Inc. (NYSE:BIO), filed a notice of proposed sale of 919 shares of the company's common stock. The filing lists an aggregate market value of $358,841.93 for the shares to be sold, with an approximate sale date of November 9, 2026. The transaction is to be conducted on the New York Stock Exchange through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing discloses that the 919 shares proposed for sale were acquired on October 24, 2025, through a restricted stock transaction directly from the issuer. The nature of payment is listed as "Not Applicable." Bio-Rad Laboratories, Inc. is headquartered at 1000 Alfred Nobel Drive, Hercules, California 94547, and carries SEC file number 001-07928. The filing states that total shares of Bio-Rad common stock outstanding number 21,832,130.
As required by Form 144, DiVincenzo represented by signing the notice that he does not know any material adverse information regarding the current and prospective operations of Bio-Rad that has not been publicly disclosed. The filing also notes nothing to report with respect to any securities of the issuer sold during the past three months by the person for whose account the securities are to be sold.
What Was Disclosed
Bio-Rad Laboratories officer Jonathan DiVincenzo filed a Form 144 on November 9, 2026, disclosing a proposed sale of 919 restricted shares of Bio-Rad common stock, acquired October 24, 2025, with an aggregate market value of $358,841.93, to be sold on the NYSE.



Please wait processing your request...